GAGA Share Market News

[hfe_template id='11223'] [ad_1] As the Nifty recorded its worst February month since the Covid, falling by 6%, heavyweight sectors IT, auto and pharma were hit by Trump led worries and the stocks in the three sectors plunged up to 33% during the month. While tech stocks’ decline rode on the fears of economic slowdown in the US, Tesla’s entry into India is making the auto counters edgy. Pharma sector’s woes hinged on reciprocal tariffs. A price analysis of the stocks in the aforementioned sectors reveals the rout. At the index level, Nifty IT is the worst performer in February with 11% monthly fall and all the 10 stocks saw their share price erode in the month gone by. The auto sector benchmark Nifty Auto declined 8% over a month while the Nifty Pharma is down 5%. IT stocks performance snapshot Midcap IT counter Mphasis has fallen by 22% and is followed by LTIMindtree and Tata Consultancy Services (TCS) which are down by 18% and 14%, respectively. Others like Coforge, L...

[hfe_template id='11223'] [ad_1] An ET poll that surveyed 30 stock market participants -- fund managers and brokers -- shows Indian equities could notch up gains, with Nifty expected to touch 25,000-27,500 by December. However, this would happen only after further declines from current levels due to foreign selling, slowing corporate earnings, high valuations and a new government in the US creating uncertainty. Of the 30 brokers and fund managers surveyed in the ET poll, 71% said the market could fall further from the current level, with 45% expecting a decline of as much as 10%. While most participants in the poll recommended staying away from FMCG, auto and real estate sectors, they saw banks, IT and pharma performing better. Banking sector prospects for investors in 2025 A significant profit milestone awaits India's public sector banks in 2024-25, and low NPAs and healthy credit growth are likely to combine to drive their profits past the Rs 1.5 lakh crore mark du...

[hfe_template id='11223'] [ad_1] Shares of Lupin will remain in focus on Thursday after the drugmaker received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for HIV tablets emtricitabine and tenofovir alafenamide tablets, 200 mg/25 mg. "We wish to confirm that the Company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg, to market a generic equivalent of Descovy® Tablets, 200 mg/25 mg of Gilead Sciences, Inc," Lupin said in an exchange filing. The approval allows Lupin to market a generic version of Descovy tablets, a product originally developed by Gilead Sciences Inc. Lupin is one of the first companies to receive approval for this generic formulation, making it eligible for 180 days of shared generic exclusivity in the US market. The product will be manu...

[hfe_template id='11223'] [ad_1] Japan's Nikkei share average rose in early trade on Friday, with pharma shares rallying for a second session, although gains were limited as tech stocks followed their U.S. peers lower. Japanese exporter-heavy equity markets also got some broad support from a weaker yen versus the dollar. However, the outlook for the currency pair looks murky, with investors watching Bank of Japan Governor Kazuo Ueda's testimony in parliament after last month's surprise rate hike. Market participants are also looking forward to U.S. Federal Reserve Chair Jerome Powell's keynote speech at the annual Jackson Hole symposium later in the day. The Nikkei rose 0.2% to 38,288.79 by 0008 GMT, while the broader Topix climbed 0.32%. Pharma was among the top gainers among the Tokyo Stock Exchange's 33 industry groups, with a 1% rise. It climbed 1.56% on Thursday. Sumitomo Pharma gained 2%, while Chugai Pharmaceuticals jumped 2.9%. Electronics m...

[hfe_template id='11223'] [ad_1] While NDA has managed to go past the majority mark bagging 291 seats, the road ahead for investors should be to reconstruct their portfolios, experts say, as they see some recalibration in policies in the new regime with the Bharatiya Janata Party (BJP) failing to form the government on its own. BJP is still the single largest party with 240 seats but the results were well short of the Street's expectations and the exit polls that gave NDA a thumping majority. "Today, when actual results are lower than the market expectation, as well as the exit poll, there is a correction happening. Investors rightfully will be looking at what kind of government gets formed, what kind of analysis is done by political parties of this verdict, and what kind of policy recalibration happens," Nilesh Shah, MD, Kotak AMC, told ETNow on Tuesday, commenting on the outcome. "Now, please remember that every political party has to keep in mind wh...